Investors are excited about GlaxoSmithKline Plc’s (GSK) plan to split the firm into two entities—pharmaceuticals and consumer healthcare.
Read more: https://www.livemint.com/Money/XVEWDuE2v9R1cYPNrW4qTI/What-the-GSK-Pfizer-merger-means-for-their-Indian-units.html
The acquisition comes less than 2 months after the companies announced that they had entered into a partnership agreement for the commercialization of Alvotech’s entire pipeline of biosimilars in Japan
Read more :https://www.centerforbiosimilars.com/news/fuji-pharma-acquires-42-stake-in-biosimilar-developer-alvotech
Taiwan's major biotech manufacturing service provider Mycenax Biotech plans to buy some new drug testing platforms and a small cell strain supplier primarily in the US and Japan in 2019.
Read more : https://www.thepharmaletter.com/in-brief/brief-taiwan-s-mycenax-looking-for-acquisitions-updates-on-biosimilar
Healthcare sector may see further consolidation in 2019 with tightening of regulatory environment set to make it difficult for small players to stay afloat in a highly competitive market.
Read more at: http://economictimes.indiatimes.com/articleshow/67319829.cms?utm_source=contentofinterest&utm_medium=text&utm_campaign=cppst
Activity in the pharma sector is rife in India, with mergers and acquisition deal values doubling given
Read more : https://www.thepharmaletter.com/article/indian-drugmakers-hit-record-year-for-m-a-and-deal-values